| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Description: JNJ4796 is a novel, potent and oral bioactive fusion inhibitor of influenza virus, which neutralizes influenza A group 1 viruses by inhibiting hemagglutinin (HA)-mediated fusion. JNJ4796 was identified through structural knowledge of the interactions and mechanism of anti-stem bnAb CR6261. It mimics the functionality of the broadly neutralizing antibodies (bnAbs). Recent characterization of broadly neutralizing antibodies (bnAbs) against influenza virus identified the conserved hemagglutinin (HA) stem as a target for development of universal vaccines and therapeutics. Although several stem bnAbs are being evaluated in clinical trials, antibodies are generally unsuited for oral delivery.
| ln Vitro |
Similar to bnAb CR6261, JNJ4796 was demonstrated to work by blocking the pH-sensitive conformational changes of HA, which in turn caused the viral and endosomal membranes to fuse and release the viral DNA into the host cell [1].
|
|---|---|
| ln Vivo |
Mice were protected against lethal challenge with 25 times the median lethal dose (LD50) of the H1N1 A/Puerto Rico/8/1934 virus by oral treatment of JNJ4796. In contrast to less than 50% survival with the less potent chemical JNJ8897, twice-daily dosages of JNJ4796 at 50 and 10 mg/kg, started the day before the challenge and continued for 7 days, resulted in 100% survival at day 21. 1]. After a sublethal viral challenge (LD90), oral dosages of JNJ4796 demonstrated dose-dependent effectiveness; at doses of 15 and 5 mg/kg twice daily, 100% survival was attained [1].
|
| Animal Protocol |
Animal/Disease Models: Female BALB/cAnNCrl mice were infected intranasally with 2 × 25 μL of 25 × LD50 or 1 × LD90 of H1N1 A/Puerto Rico/8/34[1 ]
Doses: 50 and 10 mg/kg. Directions: Take orally twice (two times) daily for 7 days. Experimental Results: Day 21 survival was 100% compared to the less potent compound JNJ8897. |
| References |
| Molecular Formula |
C28H27N9O3
|
|---|---|
| Molecular Weight |
537.572484254837
|
| Exact Mass |
537.223
|
| CAS # |
2241664-16-2
|
| PubChem CID |
135302421
|
| Appearance |
White to light yellow solid powder
|
| LogP |
2.6
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
40
|
| Complexity |
881
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(C1C=C(C2=NC3C=C(C=CC=3O2)NC(C)=O)C=CN=1)N1CCN([C@@H](C2N=NN(C)N=2)C2C=CC=CC=2)CC1
|
| InChi Key |
VMAAUIZLAZYALS-RUZDIDTESA-N
|
| InChi Code |
InChI=1S/C28H27N9O3/c1-18(38)30-21-8-9-24-22(17-21)31-27(40-24)20-10-11-29-23(16-20)28(39)37-14-12-36(13-15-37)25(19-6-4-3-5-7-19)26-32-34-35(2)33-26/h3-11,16-17,25H,12-15H2,1-2H3,(H,30,38)/t25-/m1/s1
|
| Chemical Name |
N-[2-[2-[4-[(R)-(2-methyltetrazol-5-yl)-phenylmethyl]piperazine-1-carbonyl]pyridin-4-yl]-1,3-benzoxazol-5-yl]acetamide
|
| Synonyms |
JNJ-4796; JNJ4796; JNJ 4796
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~186.02 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8602 mL | 9.3011 mL | 18.6022 mL | |
| 5 mM | 0.3720 mL | 1.8602 mL | 3.7204 mL | |
| 10 mM | 0.1860 mL | 0.9301 mL | 1.8602 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA